

Heparanase—A Link between Coagulation, Angiogenesis, and Cancer

Yona Nadir, M.D., Ph.D.,* and Benjamin Brenner, M.D.

Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus and Technion–Israel Institute of Technology, Haifa, Israel

ABSTRACT

Heparanase that was cloned from and is abundant in the placenta is implicated in cell invasion, tumor metastasis, and angiogenesis. Recently we have demonstrated that heparanase may also affect the hemostatic system in a non-enzymatic manner. Heparanase was shown to up-regulate tissue factor (TF) expression and interact with tissue factor pathway inhibitor (TFPI) on the cell surface, leading to dissociation of TFPI from the cell membrane of endothelial and tumor cells, resulting in increased cell surface coagulation activity. More recently, we have shown that heparanase directly enhances TF activity, resulting in increased factor Xa production and activation of the coagulation system. Data indicate increased levels and possible involvement of heparanase in vascular complications in pregnancy. Taking into account the prometastatic and proangiogenic functions of heparanase, overexpression in human malignancies, and abundance in platelets and placenta, its involvement in the coagulation machinery is an intriguing novel arena for further research.

KEY WORDS: Heparanase, tissue factor, tissue factor pathway inhibitor, cancer

INTRODUCTION

Cancer patients have a prothrombotic state because of the ability of cancer cells to activate the coagulation system and to interact with hematopoietic cells, thus tilting the balance between procoagulants and anticoagulants.¹ Overexpression of tissue factor (TF), cancer procoagulant—a cysteine protease that activates factor X—and acquired activated protein C

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ECM, extracellular matrix; HS, heparan sulfate; HUVEC, human umbilical vein endothelial cell; IUGR, intrauterine growth-restricted; LMWH, low-molecular-weight heparin; MM, multiple myeloma; SNPs, single nucleotide polymorphism; TF, tissue factor; TFPI, tissue factor pathway inhibitor; VEGF, vascular endothelial growth factor.

Citation: Nadir Y, Brenner B. Heparanase—A Link between Coagulation, Angiogenesis, and Cancer. RMMJ 2012;3(1):e0002. doi:10.5041/RMMJ.10069

Copyright: © 2012 Nadir and Brenner. This is an open-access article. All its content, *except where otherwise noted*, is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflict of interest: No potential conflict of interest relevant to this article was reported.

* To whom correspondence should be addressed. **E-mail:** ynadir@netvision.net.il

resistance,² are thought to be the main factors for coagulopathy in malignant disorders. TF is a transmembrane receptor that is constitutively expressed in tumors, i.e. human leukemias, lymphomas, adenocarcinomas, and sarcomas.³ TF also plays a role in cellular signaling, contributing to tumor growth and metastasis.^{3,4} The only known endogenous modulator of blood coagulation initiated by TF is tissue factor pathway inhibitor (TFPI)—a plasma Kunitz-type serine protease inhibitor.^{5,6} Growing evidence suggests the involvement of tumor-derived proteins, including heparanase, in activation of the coagulation system.

HEPARANASE

Heparanase is an endo- β -D-glucuronidase capable of cleaving heparan sulfate (HS) side chains at a limited number of sites, yielding HS fragments of still appreciable size (~5–7 kDa).^{7,8} Heparanase activity has long been detected in a number of cell types and tissues. Importantly, heparanase activity correlated with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of HS cleavage and remodeling of the extracellular matrix (ECM) barrier.^{9,10} Similarly, heparanase activity was implicated in neovascularization, inflammation, and autoimmunity, involving migration of vascular endothelial cells and activated cells of the immune system.^{9–11} A single human heparanase cDNA sequence was independently reported by several groups.^{12–15} Thus, unlike the large number of proteases that can degrade polypeptides in the ECM, one major heparanase appears to be used by cells to degrade the HS side chains of HS proteoglycans. Expression of heparanase is restricted primarily to the placenta, keratinocytes, platelets, and activated cells of the immune system, with little or no expression in connective tissue cells and most normal epithelia.^{9,10} Up-regulated expression of heparanase was noted in essentially all human tumors examined, as well as in inflammation, wound healing, and diabetic nephropathy.^{9–11} During embryogenesis, the enzyme is preferentially expressed in cells of the developing vascular and nervous systems.¹⁶

PROMETASTATIC PROPERTIES OF HEPARANASE

The clinical significance of the enzyme in tumor progression emerges from a systematic evaluation of heparanase expression in primary human tumors. Immunohistochemistry, *in-situ* hybridization, RT-PCR, and real-time PCR analyses revealed that heparanase is up-regulated in essentially all human tumors examined. These include carcinomas of the colon,^{17,18} thyroid,¹⁹ liver,²⁰ pancreas,^{21,22} bladder,^{23,24} cervix,²⁵ breast,²⁶ gastric,^{27,28} prostate,²⁹ head and neck,^{30,31} as well as multiple myeloma,³² leukemia, and lymphoma.³³ In most cases, elevated levels of heparanase were detected in about 50% of the tumor specimens, with a higher incidence in pancreatic (78%) and gastric (80%) carcinomas, and in multiple myeloma (86%). In all cases, normal tissue adjacent to the malignant lesion expressed little or no detectable levels of heparanase, suggesting that epithelial cells do not normally express the enzyme. In several carcinomas, most intense heparanase staining was localized to the invasive front of the tumor,^{23,28,30} supporting a role for heparanase in cell invasion. Furthermore, patients that were diagnosed as heparanase-positive exhibited a significantly higher rate of local and distant metastasis as well as reduced postoperative survival, compared with patients that were diagnosed as heparanase-negative.^{18,22,23,28,32} Collectively, these studies provide strong clinical support for the prometastatic function of heparanase. Interestingly, patient survival was noted to correlate not only with heparanase levels, but also with its localization. In addition to its presence in the cytoplasm, heparanase was also noted to assume nuclear localization, demonstrated by cell fractionation,³⁴ and by immunostaining of cultured cells³⁴ and tumor biopsies.^{27,35} Interestingly, nuclear localization was correlated with maintained cellular differentiation³⁵ and favorable outcome of patients with gastric^{27,35} and head and neck carcinomas,³⁶ suggesting that heparanase is intimately involved in gene regulation. Whether gene transcription and maintained cellular differentiation is due to direct interaction of

heparanase with the DNA or is a consequence of heparanase-mediated nuclear-HS degradation is yet to be demonstrated. In addition, heparanase up-regulation in primary human tumors correlated in some cases with larger tumors,^{20,26,28} and with enhanced microvessel density,^{18,20,24,32} providing clinical support for the proangiogenic function of the enzyme.

HEPARANASE POLYMORPHISMS

Heparanase gene single nucleotide polymorphisms (SNPs) were characterized in Jewish populations of Israel.³⁷ Four Israeli Jewish populations (Ashkenazi, North African, Mediterranean, and Near Eastern) were examined for seven heparanase gene SNPs. Four out of seven SNPs were found to be polymorphic. Population comparisons revealed significant differences in SNPs allele frequency between Near Eastern and each of the other three populations. Genotype and allele frequencies in Jewish populations were different from non-Jewish populations, except for a certain similarity to Caucasians.³⁷ Ostrovsky et al. found an association of heparanase gene SNPs with hematological malignancies.³⁸ Genotype frequency comparisons revealed a significant association of specific SNPs with multiple myeloma (MM), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) patients. Examination of heparanase gene mRNA expression by real-time RT-PCR indicated a significantly lower heparanase expression level in ALL patients and a higher expression level in MM and AML patients, compared to healthy controls.³⁸ The findings were not verified in ALL patients from Northern Ireland.³⁹ Ralph et al. reported on an association between a specific heparanase SNP and stage of ovarian cancer disease, while the association was not found in vascular endothelial growth factor (VEGF) SNPs.⁴⁰ Further research is needed to explore the clinical relevance of heparanase polymorphism detection.

INTERACTION OF HEPARANASE WITH HEPARINS

Anticoagulant activities of cell surfaces have been predominantly attributed to HS,^{41,42} which is composed of repeating hexuronic and D-glucosamine sulfated disaccharide units. HS has been shown to exert anticoagulant activities on cells, on ECM, and in tissues due to its catalyzing function for protease inhibition by antithrombin

and subsequent complex formation.^{41–43} Moreover, cell surface HS can facilitate the catabolism of coagulation factors such as factor VIII.⁴⁴ Other coagulation inhibitors such as TFPI also associate with the luminal face of the endothelial cell plasma membrane via HS.⁴⁵ HS is also important constituents of the subendothelial basement membrane, where they cross-link various components, e.g. laminin and collagens, thereby contributing to the integrity of the blood vessel wall.⁴⁶ HS, unfractionated heparin, and other heparin derivatives have been investigated as heparanase inhibitors, and some of them exerted antimetastatic activity in animal models.⁴⁷ Both the type of the polysaccharide backbone and the degree of sulfation seem to affect the heparanase-inhibiting activity of sulfated polysaccharides.^{48,49} However, different heparin preparations display significantly different antiheparanase activity,^{48,49} indicating that this activity is also dependent on more subtle structural features. Recently, heparanase's strong affinity to heparins was utilized *in vitro* to reverse heparin's effect. Heparanase was shown to reverse the anticoagulant activity of unfractionated heparin on the coagulation pathway as well as on thrombin activity. In addition, heparanase abrogated the factor Xa inhibitory activity of low-molecular-weight heparin (LMWH). The procoagulant effects of heparanase were also exerted by its major functional heparin-binding peptide.⁵⁰

HEPARANASE AS A CO-FACTOR TO TF ACTIVITY

Tissue factor is constitutively expressed in various cell types, including pericytes adjacent to the vessel wall, but absent from the blood cell and endothelial cell surface. This localization is crucial for hemostasis since it prevents a direct contact between TF and the circulating blood. Immunohistochemical studies revealed that many tumors express high levels of TF, including leukemia cells,⁵¹ raising the possibility of a TF role in the pathogenesis of cancer.¹ We have demonstrated that heparanase overexpression in human leukemia, glioma, and breast carcinoma cells results in a marked increase in TF levels verified by immunoblot and real-time PCR analyses.⁵² Likewise, TF was induced by exogenous addition of recombinant heparanase to tumor cells and primary endothelial cells, induction that was mediated by p38 phosphorylation and correlated

with enhanced procoagulant activity. TF induction was further confirmed in heparanase-overexpressing transgenic mice and, moreover, correlated with heparanase expression levels in leukemia patients.⁵² Lately, heparanase was found to exert also non-enzymatic activities, independent of its involvement in ECM degradation and alterations in the extracellular micro-environment.⁵³ For example, inactive heparanase enhances Akt signaling and stimulates PI3K- and p38-dependent endothelial cell migration and invasion.⁵⁴ It also promotes VEGF expression via the Src pathway.⁵⁵ Up-regulation of TF adds another example of the multiple non-enzymatic functions of heparanase. Recently, we have demonstrated that heparanase may serve as a co-factor of TF, suggesting that heparanase is directly involved in activation of the coagulation cascade.⁵⁶ The findings were supported by experiments indicating that heparanase increases the level of factor Xa in the presence of TF/VIIa and the effect is enzymatically independent. The newly generated Xa had the same molecular weight as Xa cleaved by TF/VIIa and was active as depicted by increased conversion of prothrombin to thrombin. Increased Xa generation in the presence of heparanase was shown to be relevant in the clinical setting. Thus, apart from the ability of heparanase to increase Xa levels in normal human plasma, a statistically significant positive correlation was found in patients with acute leukemia and healthy donors between the plasma levels of heparanase and Xa.⁵⁶

HEPARANASE AND TFPI

TFPI is a plasma Kunitz-type serine protease inhibitor and the only known endogenous modulator of blood coagulation initiated by TF.^{5,6} TFPI concentration in plasma is increased in patients with acute myocardial infarction.^{57,58} There are also reports on the plasma levels of TFPI in relation to disseminated intravascular coagulation⁵⁹ and to other diseases, such as diabetes mellitus,⁶⁰ renal diseases,⁶¹ and cancer.^{62,63} Recently we demonstrated that exogenous addition or overexpression of heparanase by transfected cells resulted in release of TFPI from the cell surface and its accumulation in the cell culture medium.⁶⁴ Importantly, the *in-vitro* studies were supported by elevation of TFPI levels in the plasma of transgenic mice overexpressing heparanase. Moreover, increased levels of TFPI have been noted in the plasma of cancer patients,^{62,63} reflecting, possibly, induction of heparanase expression and elevation of its plasma levels revealed by a newly developed ELISA assay.⁶⁵ In human umbilical vein endothelial cell (HUVEC) and tumor-derived cell lines, release of TFPI from the cell surface correlated with enhanced TF-mediated coagulation. This effect was evident already 30 min following heparanase addition and prior to the induction of TF⁵² or TFPI expression. Thus, heparanase enhances local coagulation activity by two independent mechanisms: induction of TF expression⁵² and TFPI dissociation from the cell surface. Both




Figure 1. A model of the interaction between heparanase (Hepa), TF, and TFPI.

Heparanase interacts with TF resulting in increased generation of factor Xa and enhancement of the coagulation system. Heparanase also up-regulates TF expression and releases TFPI from the cell surface, rendering the cell surface highly procoagulant. TFPI and heparanase may circulate as a complex in the plasma.

functions require secretion of heparanase, but not its enzymatic activity. The underlying mechanism is apparently release of TFPI due to its physical interaction with the secreted heparanase, as clearly evident by co-immunoprecipitation experiments,⁶⁴ reflecting a functional interaction between heparanase and a membrane protein.

Elevated levels of heparanase may be generated locally upon degranulation of neutrophils, mast cells, and platelets,⁶⁶ further facilitating blood coagulation at the site of platelet activation. The hemostatic function of heparanase, executed by inducing TF expression and releasing TFPI from the endothelial cell surface, provides a mechanism by which heparanase contributes to tumor complication, in addition to its established proangiogenic and prometastatic activities.^{67,68}

A MODEL FOR INTERACTION BETWEEN HEPARANASE, TF, AND TFPI

Platelets and tumor cells have abundant amounts of heparanase.⁵³ Activation of the coagulation system, including platelet activation, occurs in malignant and angiogenic processes.⁶⁹ Heparanase is directly involved in activation of the coagulation system by enhancing factor Xa production in the presence of the TF/VIIa complex. Additionally, heparanase released from activated platelets and tumor cells induce up-regulation of TF in the cells. Heparanase-mediated release of TFPI from the cell surface, together with its induction of TF, renders the cell surface highly procoagulant. Heparanase may also form complexes with TFPI and circulate in the plasma, possibly binding to endothelial cells and other intravascular components, i.e. platelets and microparticles. These aspects are depicted in Figure 1.

Pregnancy causes an acquired hypercoagulable state, and women with a prior tendency to thrombosis may present with clinical symptoms of placental vascular complications. Maternal thrombophilia can be associated with placental vascular events, although 30%–50% of vascular gestational pathologies cannot be accounted for by the currently available tests for thrombophilia.⁷⁰ Thus, an understanding of the hemostasis in the placenta, especially the dominant factors that regulate the delicate hemostatic balance throughout pregnancy, is essential. Heparanase is abundant in the placenta and was originally cloned

from placenta tissue. Additionally, estrogen was found to up-regulate heparanase gene expression in human endometrium⁷¹ and breast cancer.⁷² Recently, we investigated the role of heparanase in the placenta, focusing on its effect on TF, TFPI, TFPI-2, and VEGF-A.^{73,74} In these two studies placenta samples of women with recurrent abortions and thrombophilia (weeks 6–10) were compared to control cases of pregnancy terminations and placentas of normal vaginal deliveries, and intrauterine growth-restricted (IUGR) babies were compared to control cases of elective cesarean sections, applying real-time RT-PCR and immunostaining. Sections obtained from miscarriages and vaginal and IUGR deliveries revealed increased (2–3-fold) levels of heparanase, VEGF-A, and TFPI-2 compared to placentas from controls in maternal as well as in fetal placenta elements. A possible common denominator of the cases is vascular insufficiency: in vaginal deliveries lasting intermittently for a few hours; in miscarriages and IUGR babies it may represent a prolonged state. As heparanase directly activates the coagulation system,⁵⁶ increased heparanase found in the placentas may contribute to placental vascular complications as summarized in Figure 2.




Figure 2. Heparanase, TFPI-2, and VEGF-A are elevated in placentas with vascular insufficiency.

A schematic summary of two studies^{73,74} implying elevated levels of heparanase, TFPI-2, and VEGF-A in placentas of women with recurrent fetal losses, IUGR deliveries, and normal vaginal deliveries. In these three conditions vascular insufficiency occurs. As heparanase has a procoagulant role, it potentially can contribute to thrombosis in these placentas.

CONCLUSIONS

Heparanase was recently revealed as an important modulator of blood coagulation. The elevation of heparanase levels in human tumors, together with the prothrombotic state of most neoplasms, suggests possible clinical relevance of the procoagulant function of heparanase. In addition its increased levels in pregnancy vascular complications accentuate heparanase significance in other proangiogenic states. In order to augment the understanding of heparanase we lately developed an assay to evaluate heparanase procoagulant activity in the plasma,⁷⁵ enabling further extensive research in the field. Targeting domains of heparanase that mediate its enzymatic activity-dependent and independent functions may prove beneficial for patients with proangiogenic and prothrombotic conditions.

REFERENCES

- De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. *Crit Rev Oncol Hematol* 2004;50:187–96. [Full Text](#)
- Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. *Am J Med* 2001;110:91–6. [Full Text](#)
- Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. *Arterioscler Thromb Vasc Biol* 2005;25:47–56.
- Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. *Semin Thromb Hemost* 2006;32:24–32. [Full Text](#)
- Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. *Arterioscler Thromb Vasc Biol* 2002;22:539–48. [Full Text](#)
- Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. *J Pathol* 2006;208:327–39. [Full Text](#)
- Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. *Biochem J* 1998;330:1341–50.
- Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. *J Biol Chem* 1998;273:18770–7. [Full Text](#)
- Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. *Biochim Biophys Acta* 2001;1471:M99–108.
- Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. *J Clin Invest* 2001;108:341–7.
- Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. *Trends Biochem Sci* 2000;25:349–51. [Full Text](#)
- Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. *Nat Med* 1999;5:803–9. [Full Text](#)
- Kussie PH, Hulmes JD, Ludwig DL, et al. Cloning and functional expression of a human heparanase gene. *Biochem Biophys Res Commun* 1999;261:183–7. [Full Text](#)
- Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. *J Biol Chem* 1999;274:24153–60. [Full Text](#)
- Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. *Nat Med* 1999;5:793–802. [Full Text](#)
- Goldshmidt O, Zcharia E, Aingorn H, et al. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. *J Biol Chem* 2001;276:29178–7. [Full Text](#)
- Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. *Am J Pathol* 2000;157:1167–75. [Full Text](#)
- Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. *J Surg Oncol* 2004;87:174–81. [Full Text](#)
- Xu X, Quiros RM, Maxhimer JB, et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. *Clin Cancer Res* 2003;9:5968–79.
- El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparinase and basic fibroblast growth factor expressions in hepatocellular carcinoma. *Clin Cancer Res* 2001;7:1299–305.
- Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. Human heparanase-1 gene expression in pancreatic adenocarcinoma. *J Gastrointest Surg* 2002;6:167–72. [Full Text](#)
- Rohloff J, Zinke J, Schoppmeyer K, et al. Heparanase expression is a prognostic indicator for

- postoperative survival in pancreatic adenocarcinoma. *Br J Cancer* 2002;86:1270–5. [Full Text](#)
23. Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer. *J Urol* 2001;166:1286–90. [Full Text](#)
 24. Gohji K, Hirano H, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. *Int J Cancer* 2001;95:295–301. [Full Text](#)
 25. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. *Ann Oncol* 2003;14:1505–10. [Full Text](#)
 26. Maxhimer JB, Quiros RM, Stewart R, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. *Surgery* 2002;132:326–33. [Full Text](#)
 27. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. *Lab Invest* 2003;83: 613–22.
 28. Tang W, Nakamura Y, Tsujimoto M, et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. *Mod Pathol* 2002;15:593–8. [Full Text](#)
 29. Ogishima T, Shiina H, Breault JE, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. *Clin Cancer Res* 2005;11:1028–36.
 30. Beckhove P, Helmke BM, Ziouta Y, et al. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis. *Clin Cancer Res* 2005;11:2899–906. [Full Text](#)
 31. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. *Jpn J Cancer Res* 2001;92: 1062–73.
 32. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. *Cancer Res* 2003;63: 8749–56.
 33. Bitan M, Polliack A, Zecchina G, et al. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. *Exp Hematol* 2002;30:34–41. [Full Text](#)
 34. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O. Human heparanase nuclear localization and enzymatic activity. *Lab Invest* 2004;84:535–44. [Full Text](#)
 35. Ohkawa T, Naomoto Y, Takaoka M, et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. *Lab Invest* 2004;84:1289–304. [Full Text](#)
 36. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. *Neoplasia* 2006;8:1055–61. [Full Text](#)
 37. Ostrovsky O, Korostishevsky M, Levite I, et al. Characterization of HPSE gene single nucleotide polymorphisms in Jewish populations of Israel. *Acta Haematol* 2007;117:57–64. [Full Text](#)
 38. Ostrovsky O, Korostishevsky M, Levite I, et al. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. *Leukemia* 2007;21:2296–303. [Full Text](#)
 39. Winter PC, McMullin MF, Catherwood MA. Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukaemia in patients from Northern Ireland. *Leukemia* 2008;22:1629–31; discussion 1631–3.
 40. Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R, Jayson GC. Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. *Cancer Sci* 2007;98:844–9. [Full Text](#)
 41. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Natural anticoagulant pathways in normal and transplanted human hearts. *J Heart Lung Transplant* 1992;11:342–7.
 42. de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulant active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. *J Cell Biol* 1990;111:1293–304. [Full Text](#)
 43. Girardin EP, Hajmohammadi S, Birmele B, Helisch A, Shworak NW, de Agostini AI. Synthesis of anticoagulant active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool. *J Biol Chem* 2005;280:38059–70. [Full Text](#)
 44. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. *J Biol Chem* 2001;276:11970–9. [Full Text](#)
 45. Ho G, Broze GJ Jr, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation

- of tissue factor pathway inhibitor-coagulation factor Xa complexes. *J Biol Chem* 1997;272:16838–44. [Full Text](#)
46. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. *Nat Rev Mol Cell Biol* 2005; 6:646–56. [Full Text](#)
 47. Parish CR, Coombe DR, Jakobsen KB, Bennett FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. *Int J Cancer* 1987;40:511–8. [Full Text](#)
 48. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. *Blood* 1987;70:551–7.
 49. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. *J Biol Chem* 2005;280:12103–13. [Full Text](#)
 50. Katz BZ, Muhl L, Zwang E, et al. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms. *Thromb Haemost* 2007;98:1193–9.
 51. Nadir Y, Katz T, Sarig G, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. *Haematologica* 2005;90:1549–56.
 52. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. *J Thromb Haemost* 2006;4:2443–51. [Full Text](#)
 53. Ilan N, Elkin M, Vlodaysky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. *Int J Biochem Cell Biol* 2006;38:2018–39. [Full Text](#)
 54. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodaysky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. *J Biol Chem* 2004;279:23536–41. [Full Text](#)
 55. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodaysky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. *Cancer Res* 2006;66:1455–63. [Full Text](#)
 56. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodaysky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. *Haematologica* 2010; 95:1927–34. [Full Text](#)
 57. Kamikura Y, Wada H, Yamada A, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. *Am J Hematol* 1997; 55:183–7. [Full Text](#)
 58. Misumi K, Ogawa H, Yasue H, et al. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. *Jpn Circ J* 1998;62:419–24. [Full Text](#)
 59. Yamamuro M, Wada H, Kumeda K, et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. *Blood Coagul Fibrinolysis* 1998;9:491–7. [Full Text](#)
 60. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. *Diabetes Care* 2002;25:1340–5. [Full Text](#)
 61. Al-Mugeiren MM, Abdel Gader AG, Al-Rasheed SA, Al-Salloum AA. Tissue factor pathway inhibitor in childhood nephrotic syndrome. *Pediatr Nephrol* 2006; 21:771–7. [Full Text](#)
 62. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. *Br J Haematol* 1998; 102:889–95. [Full Text](#)
 63. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. *Thromb Res* 2002;105:33–6. [Full Text](#)
 64. Nadir Y, Brenner B, Gingis-Velitski S, et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. *Thromb Haemost* 2008; 99:133–41.
 65. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. *Biochem Biophys Res Commun* 2006;341:958–63. [Full Text](#)
 66. Vlodaysky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. *Invasion Metastasis* 1992;12:112–27.
 67. Vlodaysky I, Abboud-Jarrou G, Elkin M, et al. The impact of heparanase and heparin on cancer metastasis and angiogenesis. *Pathophysiol Haemost Thromb* 2006;35:116–27. [Full Text](#)

68. Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodaysky I, Ben-Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. *Histopathology* 2006;49:188–93. [Full Text](#)
69. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. *Arterioscler Thromb Vasc Biol* 2005;25:1545–50. [Full Text](#)
70. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. *Semin Thromb Hemost* 2003;29:175–84. [Full Text](#)
71. Xu X, Ding J, Rao G, et al. Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. *Hum Reprod* 2007;22:927–37. [Full Text](#)
72. Elkin M, Cohen I, Zcharia E, et al. Regulation of heparanase gene expression by estrogen in breast cancer. *Cancer Res* 2003;63:8821–6.
73. Nadir Y, Henig I, Naroditzky I, Paz B, Vlodaysky I, Brenner B. Involvement of heparanase in early pregnancy losses. *Thromb Res* 2010;125:e251–7. [Full Text](#)
74. Nadir Y, Kenig Y, Drugan A, Zcharia E, Brenner B. Involvement of heparanase in vaginal and cesarean section deliveries. *Thromb Res* 2010;126:e444–50. [Full Text](#)
75. Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B. An assay to evaluate heparanase procoagulant activity. *Thromb Res* 2011;128:e3–8.